By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: New Weight Loss Drugs Come to Market as AMA Recognizes Obesity as Disease
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > New Weight Loss Drugs Come to Market as AMA Recognizes Obesity as Disease
Public Health

New Weight Loss Drugs Come to Market as AMA Recognizes Obesity as Disease

Jennifer Bragg
Jennifer Bragg
Share
5 Min Read
obesity recognized as disease
SHARE

obesity recognized as diseaseOver the summer, the American Medical Association officially labeled obesity a disease. The new designation informed 78 million American adults and 12 million American children that they have a condition requiring medical treatment.

obesity recognized as diseaseOver the summer, the American Medical Association officially labeled obesity a disease. The new designation informed 78 million American adults and 12 million American children that they have a condition requiring medical treatment.

If obesity is, in fact, a disease, the majority of Americans have it. Over one third of Americans are obese and well over two-thirds are overweight. And here in the U.S., we treat diseases with drugs. Coincidentally, two new drugs, Belviq and Qsymia, entered the market shortly after the AMA began calling obesity a disease. These drugs are the first weight loss medications to receive FDA approval in over a decade.

Until very recently, much of the medical community considered weight loss drugs to be vanity products. However, with the rise in obesity in the United States comes a rise in heart disease, depression, type 2 diabetes and some cancers. These drugs may have the potential to prevent the onset of some of these conditions.

More Read

Red Light Cameras Save Lives
How Will the Supply Chain Support Vaccine Distribution?
Q and A: Addressing an Enormous Public Health Problem with a Simple Technology Solution
Cartoon Characters Impact Kids’ Cereal Preferences
Can CBD Oil Treat Anxiety? Facts, Research and Precautions

Belviq and Qsymia are recommended for patients with similar problems. Both are recommended for obesity, or a body mass index higher than 30. If you are overweight, with a body mass index of 27 or higher, most doctors will recommend that you have type 2 diabetes, high blood pressure or high cholesterol before using either medication. Pregnant women should not take these drugs.

The major difference between Belviq and most other weight loss drugs or weight management aids is that it actually provides a feeling of satiety. The drug works on serotonin transmitters in the brain to make users feel full. They simply don’t have to eat as much as they would without it.

Qsymia combines two currently approved drugs. The first is an appetite suppressant called phentermine. This is the safer part of the infamous fen-phen weight loss aid. The other half is a seizure and/or migraine drug called topiramate, which can cause feelings of fullness, and increase calorie burning.

“Obesity threatens the overall well being of patients and is a major public health concern,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research in a press release. “Qsymia, used responsibly in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, provides another treatment option for chronic weight management in Americans who are obese or are overweight and have at least one weight-related comorbid condition.”

Neither Belviq nor Qsymia is a miracle cure. Weight loss with both drugs is moderate for most users. Patients in clinical trials went from an average 227 pounds to 204 pounds on Qsymia. On Belviq, patients’ average weight dropped from 220 to 207.

About 47 percent of Belviq users without type 2 diabetes lost at least 5 percent of their body weight compared with about 23 percent of patients treated with placebo. In users with type 2 diabetes, about 38 percent of patients treated with Belviq and 16 percent treated with placebo lost at least 5 percent of their body weight. Belviq labeling recommends that drug use be discontinued in patients fail to lose 5 percent of their body weight after 12 weeks of treatment, as these patients are unlikely to achieve clinically meaningful weight loss with continued treatment.

Diet drugs have been around in different forms for years. It will likely take years to see if either of these new drugs makes a dent in America’s obesity epidemic.

(obesity / shutterstock)

TAGGED:obesityPerson-Centered HealthCare
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

TruTouch Technologies Receives US Patent For Non-Invasive Alcohol Detection Device

January 4, 2012
non-clinical care factors in health outcomes
Health ReformMobile HealthPublic Health

Addressing Non-Clinical Care Factors in Health Outcomes

November 15, 2013
health policy sequestration
BusinessFinanceHealth ReformHospital AdministrationNewsPolicy & LawPublic Health

Sequestration and Healthcare: What Organizations are Affected? (Part 1)

March 15, 2013

Health Affairs Briefing Addresses Costly Consequences of Diabetes Treatment in America

January 12, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?